Purchase this article with an account.
J.B. Serle, R. Wang, W.M. Peterson, R. Plourde, B.R. Yerxa, S.M. Podos; Effect of 5-MCA-NAT, a Putative Melatonin MT3 Receptor Agonist, on Intraocular Pressure (IOP) in Glaucomatous Monkey Eyes . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4235.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: 5-MCA-NAT, a putative melatonin MT3 receptor agonist, reduced IOP in rabbits. This study evaluates the effect of topical application of 5-MCA-NAT on IOP in monkey eyes with laser-induced unilateral glaucoma. Methods: A multiple-dose study was performed in 8 glaucomatous monkey eyes. One 25 µl drop of 5-MCA-NAT (2%) was applied topically to the glaucomatous eye at 9:30 a.m. and 3:30 p.m. for 5 consecutive days. IOP was measured hourly for 6 hrs beginning at 9:30 a.m. for one baseline day, one vehicle-treated day, and treatment days 1, 3, and 5 with 5-MCA-NAT. Results: Compared to vehicle treatment, twice daily administration of 5-MCA-NAT for 5 days reduced (p<0.05) IOP from 1 hr to 5 hrs after the first dose, and lasted at least 18 hrs after the fifth dose. The ocular hypotensive effect of 5-MCA-NAT was enhanced with repeated dosing. The maximum reduction (p<0.001) of IOP occurred at 3 hrs after each morning dose, and was 4.0 ± 0.5 (mean ± SEM) mmHg (10%) on day 1, 5.6 ± 0.8 mmHg (15%) on day 3, and 7.0 ± 1.1 mmHg (19%) on day 5. Adverse ocular or systemic side effects were not observed during the 5 days of treatment. Conclusions: 5-MCA-NAT, a putative melatonin MT3 receptor analog, reduces IOP in glaucomatous monkey eyes. Melatonin agonists with activity on the putative MT3 receptor may have clinical potential for treating elevated IOP.
This PDF is available to Subscribers Only